Clinical trial
Docetaxel and Epirubicin in Advanced Gastric Cancer
NCT00375999 · Yonsei University, Other · Completed
Key facts
| NCT number | NCT00375999 |
|---|---|
| Title | Docetaxel and Epirubicin in Advanced Gastric Cancer |
| Official title | A Phase II Study of Docetaxel and Epirubicin Combination in Patients With Advanced Gastric Cancer. |
| Lead sponsor | Yonsei University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stomach Neoplasms |
| Intervention type | Drug |
| Interventions | Docetaxel and epirubicin |
| Enrollment | 34 |
| Start date | Sep 1, 2006 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Sep 14, 2006 |
| Last update posted | Mar 3, 2014 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: